Bicocca Open Archive

Logo unimib boa
LAPADULA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.669
EU - Europa 3.306
AS - Asia 1.851
SA - Sud America 29
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 11.867
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.549
SG - Singapore 804
IT - Italia 683
SE - Svezia 576
IE - Irlanda 570
HK - Hong Kong 468
DE - Germania 439
RU - Federazione Russa 424
CN - Cina 297
UA - Ucraina 148
GB - Regno Unito 129
ID - Indonesia 108
CA - Canada 91
FI - Finlandia 82
AT - Austria 80
VN - Vietnam 52
IN - India 47
RO - Romania 44
TR - Turchia 36
DK - Danimarca 30
FR - Francia 29
MX - Messico 28
NL - Olanda 23
CZ - Repubblica Ceca 20
BE - Belgio 15
BR - Brasile 13
CO - Colombia 11
IR - Iran 9
KR - Corea 7
PH - Filippine 6
CL - Cile 4
CH - Svizzera 3
GE - Georgia 3
AM - Armenia 2
AZ - Azerbaigian 2
EE - Estonia 2
EG - Egitto 2
ET - Etiopia 2
EU - Europa 2
IL - Israele 2
KE - Kenya 2
LU - Lussemburgo 2
NZ - Nuova Zelanda 2
PK - Pakistan 2
PL - Polonia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
BY - Bielorussia 1
CR - Costa Rica 1
EC - Ecuador 1
JO - Giordania 1
JP - Giappone 1
KZ - Kazakistan 1
LT - Lituania 1
MY - Malesia 1
NO - Norvegia 1
PT - Portogallo 1
TH - Thailandia 1
TW - Taiwan 1
Totale 11.867
Salva come PNG Salva come JPEG
Città #
Ann Arbor 987
Singapore 713
Fairfield 590
Dublin 554
Woodbridge 491
Hong Kong 468
Chandler 466
Houston 412
Ashburn 345
Frankfurt am Main 337
Wilmington 285
New York 248
Santa Clara 241
Princeton 229
Seattle 216
Cambridge 196
Jacksonville 193
Milan 150
Dearborn 130
Altamura 111
Lawrence 111
Jakarta 108
Shanghai 66
Vienna 66
San Diego 63
Nanjing 52
Dong Ket 44
Galati 43
Helsinki 37
Lachine 37
Andover 30
London 29
Boardman 27
Rome 25
Dallas 23
Beijing 22
Pune 22
Toronto 20
Nuremberg 19
Fremont 18
Los Angeles 18
Cuauhtémoc 17
Falls Church 17
Norwalk 17
Ottawa 17
Guangzhou 16
Busto Arsizio 15
Hebei 15
Munich 15
Palermo 15
Brno 14
Brussels 14
Shenyang 14
Chicago 13
Bogotá 11
Monza 11
Washington 11
Florence 10
Nanchang 10
Tianjin 10
Lissone 8
Shenzhen 8
Lappeenranta 7
Brescia 6
Changsha 6
Detroit 6
Kunming 6
Redmond 6
Turin 6
Bollate 5
Bresso 5
Edmonton 5
Geumjeong-gu 5
Jinan 5
Loreto 5
Mountain View 5
Olomouc 5
San Francisco 5
Vijayawada 5
Como 4
Hyderabad 4
Kilburn 4
Melzo 4
Naples 4
Ningbo 4
Padova 4
Pisa 4
Acton 3
Bologna 3
Bonndorf 3
Caserta 3
Cinisello Balsamo 3
Clearwater 3
Gradara 3
Hangzhou 3
Hounslow 3
Jiaxing 3
Kiev 3
Leawood 3
Legnano 3
Totale 8.684
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 292
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 223
Remdesivir use in patients requiring mechanical ventilation due to COVID-19 216
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 212
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 205
The high volume of patients admitted during the SARS-CoV-2 pandemic has an independent harmful impact on in-hospital mortality from COVID-19 204
Caratteristiche di una coorte di pazienti con co-infezione HIV/HCV: i dati dell’Ambulatorio di Malattie Infettive dell’Ospedale San Gerardo di Monza 203
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 202
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 196
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 193
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 176
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 174
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 174
HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation 174
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 173
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 171
Unmasking tuberculosis in the era of antiretroviral treatment 167
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 166
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 166
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 166
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 165
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances 162
Infezione disseminata da Mycobacterium avium complex con batteriemia persistente in un paziente AIDS-presenter [Disseminated Mycobacterium avium complex infection with persistent bacteremia in an AIDS-presenter patient] 158
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: A cross-sectional observational study 151
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 150
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 150
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 146
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 141
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 136
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 135
miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis 130
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 127
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 127
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 127
To the editor 126
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 126
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 121
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 117
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 116
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 116
Beware of biases in observational studies on anti-spike monoclonal antibodies 116
Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: The D:A:D study 112
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 111
Associations between immune depression and cardiovascular events in HIV infection 106
COVID-19 Mortality and Stress to the Hospital System From High Patient Load 104
Malassorbimento intestinale della terapia antiretrovirale in un paziente affetto da AIDS e micobatteriosi atipica disseminata 101
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 100
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 98
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: A comparison of the D: A: D CVD risk equation and general population CVD risk equations 95
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 94
Compassionate Use of Remdesivir in Children With Severe COVID-19 86
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 79
Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19 77
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors 76
Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART 75
Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: A cross-sectional study 74
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 74
Pharmacotherapy of HIV: Focus on Etravirine 74
Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: A single center analysis 73
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV 73
Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: A case report 73
Predictors of AIDS-defining events among advanced naïve patients after HAART 72
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort 71
Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients 70
CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load 70
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 70
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 70
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals 69
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 69
Imported ciprofloxacin-resistant Neisseria meningitidis 68
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 67
Screening and management of HIV-2-infected individuals in Northern Italy 66
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 65
Behavioural survey and street-based HIV and HCV rapid testing programme among transgender sex workers 65
No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients [2] 64
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients 64
Unexpected viral relapses in hepatitis C virus–infected patients diagnosed with hepatocellular carcinoma during treatment with direct-acting antivirals 63
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the italian atazanavir expanded access program and master cohorts 62
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 61
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts >= 200 cells/mm(3) 61
Prolonged higher dose methylprednisolone vs. conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS) 61
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 60
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 60
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis 60
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy 60
Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study 59
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 59
Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapy 59
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 59
Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitors 56
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 54
Early prone positioning does not improve the outcome of patients with mild pneumonia due to SARS-CoV-2: results from an open-label, randomised controlled trial (the EPCoT Study) 53
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 53
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation 52
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy 50
High-risk HPV genotypes are associated with anal cytologic abnormalities but not with malignant histological lesions in a cohort of people with HIV (PWH) 49
In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry 48
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 48
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 47
Totale 10.914
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020693 0 0 0 0 0 0 158 119 149 94 108 65
2020/20211.242 44 74 103 153 105 67 84 125 118 131 81 157
2021/20221.481 68 88 368 136 63 111 31 113 58 72 125 248
2022/20232.134 264 585 198 156 141 377 19 114 178 28 50 24
2023/20241.798 62 52 87 47 216 459 356 67 181 54 33 184
2024/20252.677 279 718 595 216 430 244 195 0 0 0 0 0
Totale 12.555